看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。/ u8 G5 D- W! q
: k" w. }7 [! L1 P) o( K
, k- s7 }) i- p( w4 b& oCurrently available feasibility data for possible combination strategies. & n0 C' y, m* V3 t7 `6 J% X
————————————————————————————————0 M5 u/ o0 ~. Y" ^5 W# u
Combination Feasibility according to preliminary data ! E# C3 h% y& V- O3 ]
——————————————————————————————————7 I( J' }; { a. T% Y+ \
Bevacizumab + sorafenib Yes, reduced dose
D) k: u3 @8 H8 Q6 o" `7 s; x4 ~Bevacizumab + sunitinib† No 0 h9 N D( @: d2 }9 D6 c. P3 R
Bevacizumab + temsirolimus Yes 6 {1 r+ {% A6 R) _( H7 ]! z+ P
Bevacizumab + everolimus Yes
" x0 d" ]5 W/ Q/ l' e9 ?# ^3 A5 G4 i1 [Sorafenib + sunitinib ? 8 b8 u- \3 S' x' l- e- Z
Sorafenib + temsirolimus Yes, reduced dose 7 K1 \5 o& t4 C0 a3 Z' ]- W% ~
Sorafenib + everolimus Yes, reduced dose
: v, ~8 c8 R1 `2 R3 ]% C% pSunitinib + temsirolimus† No $ h& j- {4 w. `7 _; E2 [
Sunitinib + everolimus ?
$ w) v/ `& s, ^+ U' I$ mTemsirolimus + everolimus ?
$ k7 |( W" ~) }————————————————————7 ^0 c% D% D- o% R" D2 b! Y0 L
†Led to US FDA warning.
: E3 l$ E" w7 ]* L+ A2 V, P, a; v1 C?: As yet unattempted combination.
. R( @/ Z7 d p/ h1 \1 L e$ a |